This is actually the first authorization of a drug for treating this life-threatening disease, and the 1st approval for use of Soliris in children, stated Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Medication Evaluation and Analysis. This authorization underscores how an increased understanding of the biology of an illness and of how a medication interacts with that procedure can expedite drug development. Patients treated with Soliris also exhibited improvement in platelet counts and additional blood parameters that correlate with aHUS disease activity. Related StoriesStudy shows post-stroke loss of speech could be recoveredMore research needed before recommending antidepressants, Alzheimer's disease medications for stroke recovery: StudyLowering blood pressure below currently recommended targets reduces threat of stroke, center attackThe most common unwanted effects seen in individuals treated with Soliris for aHUS included high blood circulation pressure , diarrhea, headache, anemia, vomiting, nausea, top respiratory and urinary system infections, and a decrease in white blood cells .‘I understand from my very own experience people will need whatever they need to, and in raising quantities, to escape their pain. I drank heavily in an attempt to manage my pain,’ said Frampton. ‘Finally, after becoming diagnosed and treated properly, I am able to manage my pain and my life appropriately.’ ‘We need to look at the bigger picture. Medications and remedies are only as effective as the physicians who prescribe them and the knowledge of the individuals who receive them. There is no cookie cutter method of treating pain. A comprehensive pain strategy is paramount to addressing this complex problem.’ Additional Canadian provinces, like Alberta, Nova and Quebec Scotia, have implemented discomfort strategies that may help inform the Ontario encounter successfully.